中文(繁體)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Individualized Blood Pressure Management in Patients Undergoing Cardiac Surgery

只有註冊用戶可以翻譯文章
登陸註冊
鏈接已保存到剪貼板
狀態
贊助商
Meshalkin Research Institute of Pathology of Circulation

關鍵詞

抽象

This pilot randomized-controlled study will determine the feasibility of large study comparing individualized versus standard blood pressure (BP) management in patients undergoing cardiac surgery under cardiopulmonary bypass (CPB). Our hypothesis is that maintaining higher BP levels based on preoperative measurements will reduce the incidence of major complications (composite outcome).

描述

Adequate hemodynamic control is a cornerstone in management in patients undergoing different types of surgery. Among all perioperative risk factors, the association between perioperative hypotension and adverse clinical outcomes in noncardiac and cardiac surgery patients is well defined.

Numerous factors are responsible for development of perioperative hypotension. They include but not limited to perioperative use of renin-angiotensin-aldosterone system and calcium channel blockers, hypovolemia, hemodilution, bleeding and inflammatory response syndrome.

To date, several evidence has been accumulated indicating that intraoperational hypertension can be hazardous.

It was shown that even short durations (1 to 5 min) of an intraoperative mean arterial pressure < 55 mmHg were associated with myocardial injuries and acute kidney injury (AKI).

Results of recent large retrospective cohort study conducted in adult patients who underwent cardiac surgery requiring CPB showed that postoperative stroke was strongly associated with sustained mean arterial pressure of less than 64 mmHg during cardiopulmonary bypass.

In patients undergoing CABG the overall incidence of combined cardiac and neurologic complications was significantly lower in the group where MAP during CPB was relatively high (80-110 mmHg) than in the low pressure group (MAP 50-60 mmHg) (p = 0.026). For each of the individual outcomes the trend favored the high pressure group.

Therefore, MAP may be an important intraoperative therapeutic hemodynamic target to reduce the incidence of complications in patients undergoing CPB.

日期

最後驗證: 10/31/2019
首次提交: 10/02/2018
提交的預估入學人數: 12/20/2018
首次發布: 12/23/2018
上次提交的更新: 11/19/2019
最近更新發布: 11/21/2019
實際學習開始日期: 01/20/2019
預計主要完成日期: 03/09/2020
預計完成日期: 04/09/2020

狀況或疾病

Cardiac Surgery

干預/治療

Other: Individualized BP group

Other: Standard treatment group

-

手臂組

干預/治療
Experimental: Individualized BP group
Individualized intraoperative BP management
Other: Individualized BP group
In the treatment group, the nurse will measure resting blood pressure three times in the ward one day before surgery (after a 5-min rest while lying supine). Average measurement will be used to calculate mean arterial pressure (MAP). Before and after CPB patients will receive continuous infusion of norepinephrine to maintain MAP within ± 10% of patients resting MAP. If targeted MAP during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will used. After CPB, the choice of vasopressors/inotropes to maintain predefined MAP will be left on attending anesthesiologists based on patient status.
Placebo Comparator: Standard treatment group
Standard intraoperative BP management
Other: Standard treatment group
Standard treatment strategy will be used aiming to maintain pre-bypass and post-bypass MAP at 65-75 mm Hg. MAP during CPB will be maintained at 50-60 mm Hg. If MAP of 50-60 mm Hg during CPB could not be achieved after increasing pump-flow (not more than 130%), infusion of norepinephrine will be started. No vasodilators will be used if MAP will exceed predefined range.

資格標準

有資格學習的年齡 18 Years 至 18 Years
有資格學習的性別All
接受健康志願者
標準

Inclusion Criteria:

- ≥18 years old

- Signed informed consent

- Elective cardiac surgery under CPB (CABG or valve surgery)

Exclusion Criteria:

- Unstable Coronary Artery Disease: Recent (< 6 weeks) myocardial infarction, unstable angina, severe (> 70%) left main coronary artery stenosis

- Uncontrolled hypertension preoperatively (SBP > 160 mm Hg)

- Critical preoperative state (ventricular tachycardia or ventricular fibrillation or aborted sudden death, preoperative cardiac massage, preoperative ventilation before anesthetic room, hemodynamic instability, preoperative inotropes or intraaortic balloon pumping, preoperative severe acute renal failure (anuria or oliguria <10ml/hr)

- Planned surgery on aorta

- Emergency surgery

- Pregnancy

- Current enrollment into another randomized controlled trial (in the last 30 days)

- Previous enrollment and randomization into current study

- Glomerular filtration rate ≤59 ml/min/1.73m2 (Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation)

結果

主要結果指標

1. Compliance with the protocol [Operative day 1]

Successful compliance with protocol is defined as ≥ 90% of prescribed intervention being administered across all patients.

2. Successful recruitment rate [12 month]

Successful recruitment rate will be defined as recruitment of 2 patients per week.

次要成果指標

1. Postoperative creatinine concentration [3 days after surgery]

Plasma creatinine level will be measured daily during 3 postoperative days.

2. Postoperative cardiac troponin I level [12 hours after surgery]

Cardiac troponin I level wil be measured in the time frame from 6 to 12 hours postoperatively.

3. Intraoperative blood pressure [Operative day 1]

Intraoperative blood pressure (mean, systolic and diastolic) will be registered every 5 minutes intraoperatively using invasive blood pressure monitoring system.

4. Rate of postoperative complications [30 days after surgery]

Postoperative complications (myocardial infarction, atrial fibrillation, stroke, delirium, need for renal replacement therapy, infection, reexploration for bleeding) will be defined according to standard European Society of Anaesthesiology/European Society of Intensive Care Medicine definitions where possible.

5. Postoperative blood loss [Postoperative day 1]

Drainage volume (ml/kg) will be measured in the next morning after surgery.

6. Daily Sequential Organ Failure Assessment (SOFA) score [30 days after surgery]

Organ failure will be assessed by using Sequential Organ Failure Assessment (SOFA) score which will be recorded daily until patient discharge from the ICU. The score is based on six different scores, one each for the respiratory, cardiovascular, hepatic, coagulation, renal and neurological systems. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure). The score ranges from 0 to 24 points (the higher the score, the higher the mortality).

7. Peak concentration of lactate during CPB and up to 24 hours after surgery [Postoperative day 1]

Lactate values (mmol/l) will be measured every 6 hours during the first 24 postoperative hours.

8. Oxygen delivery during CPB [Operative day 1]

Oxygen delivery during CPB will be calculated according to the standard formula (pump flow x O2 arterial content).

9. Cerebral oxygenation (near infrared spectroscopy) [Operative day1]

Number of cerebral desaturations will be recorded intraoperatively.

10. Ventilation > 24 hours [30 days after surgery]

Number of patients with duration of ventilation more than 24 h.

11. Duration of ICU stay and hospitalization [30 days after surgery]

Number of postoperative days spent in the ICU and in the hospital will be counted.

12. 30-day all-cause mortality [30 days after surgery]

Number of patients who will die within 30-day after surgery from any cause

13. Need for blood transfusions [30 days after surgery]

Number of patients who will need transfusions of any blood products (RBC, fresh frozen plasma, platelets, cryoprecipitate).

加入我們的臉書專頁

科學支持的最完整的草藥數據庫

  • 支持55種語言
  • 科學支持的草藥療法
  • 通過圖像識別草藥
  • 交互式GPS地圖-在位置標記草藥(即將推出)
  • 閱讀與您的搜索相關的科學出版物
  • 通過藥效搜索藥草
  • 組織您的興趣並及時了解新聞研究,臨床試驗和專利

輸入症狀或疾病,並閱讀可能有用的草藥,輸入草藥並查看其所針對的疾病和症狀。
*所有信息均基於已發表的科學研究

Google Play badgeApp Store badge